Evidence map›Paper›PMID 31430007›Full record

ArticleAngewandte Chemie (International ed. in English)2019

Development of Zinc-Specific iCEST MRI as an Imaging Biomarker for Prostate Cancer.

Yue Yuan, Zhiliang Wei, Chengyan Chu, Jia Zhang, Xiaolei Song, Piotr Walczak, Jeff W M Bulte

Open access · greenAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Fast Ion-Chelate Dissociation Rate forJournal of the American Chemical Society · 2021
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Advances of Zinc Signaling Studies in Prostate Cancer.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yue YuanThe Russell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-2653-8963
Zhiliang WeiThe Russell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Chengyan ChuThe Russell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jia ZhangThe Russell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Xiaolei SongThe Russell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Piotr WalczakThe Russell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jeff W M BulteThe Russell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-1202-1610
Johns Hopkins University · US

Funding

Training/Dissemination-Resource for Molecular Imaging Agents in Precision MedicineP41EB024495 · NIBIB · UT SOUTHWESTERN MEDICAL CENTER · PI MARTIN G POMPER · 2017 to 2026
$11.8M
Developing MRI sensors for monitoring Zn2+ using iCESTR03EB018882 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI BULTE, JEFF W. · 2014 to 2015
$163k
NIBIB NIH HHS P41 EB024495NIBIB NIH HHS R03 EB018882NIH HHS R03 EB018882The Pearl and Yueh-Heng Yang Foundation
6 · The paper itself

Abstract

The healthy prostate contains the highest concentration of mobile zinc in the body. As this level decreases dramatically during the initial development of prostate cancer, in vivo detection of prostate zinc content may be applied for diagnosis of prostate cancer. Using

Indexed as

AnimalsBiomarkers, TumorCell Line, TumorContrast MediaDisease Models, AnimalEgtazic AcidFluorineHumansMagnetic Resonance ImagingMaleMiceMice, TransgenicProstatic NeoplasmsZinc1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acidBiomarkers, TumorContrast MediaEgtazic AcidFluorineZincimaging agentsMRIprostate cancerzinc

Identifiers

PMID31430007
PMCPMC7261412
OpenAlexW2974793281

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.